128 related articles for article (PubMed ID: 26260809)
1. Are predictions of cancer response to targeted drugs, based on effects in unrelated tissues, the 'Black Swan' events?
Kurbel B; Golem AZ; Kurbel S
Future Oncol; 2015; 11(16):2307-14. PubMed ID: 26260809
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
4. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
5. [New drugs in oncology: benefits, risks and challenges].
Cella D; Vervölgyi V; Wörmann B
Onkologie; 2013; 36 Suppl 5():12-9. PubMed ID: 23921801
[No Abstract] [Full Text] [Related]
6. Side effects of targeted therapies: rash.
Eaby-Sandy B; Lynch K
Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
[TBL] [Abstract][Full Text] [Related]
7. [Revision of therapeutic index for targeted treatment in kidney cancer: What if toxicity could predict efficacy?].
Grellety T; Brugères-Chakiba C; Chaminade A; Roubaud G; Ravaud A; Gross-Goupil M
Bull Cancer; 2014 Jun; 101(6):608-18. PubMed ID: 24977449
[TBL] [Abstract][Full Text] [Related]
8. Clinical guidance on the perioperative use of targeted agents in solid tumor oncology.
Mellor JD; Cassumbhoy M; Jefford M
Asia Pac J Clin Oncol; 2011 Jun; 7(2):106-13. PubMed ID: 21585689
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of targeted therapy in non-small-cell lung cancer management.
Ricciardi S; Tomao S; de Marinis F
Clin Lung Cancer; 2009 Jan; 10(1):28-35. PubMed ID: 19289369
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
11. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
12. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Ho WL; Wong H; Yau T
Acta Ophthalmol; 2013 Nov; 91(7):604-9. PubMed ID: 22970709
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeted therapy: a strategy of disillusions or optimism?
Eckhardt S
J Lab Clin Med; 2006 Mar; 147(3):108-13. PubMed ID: 16503239
[TBL] [Abstract][Full Text] [Related]
14. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
[TBL] [Abstract][Full Text] [Related]
15. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
Dai J; Belum VR; Wu S; Sibaud V; Lacouture ME
J Am Acad Dermatol; 2017 Nov; 77(5):902-910.e2. PubMed ID: 28918974
[TBL] [Abstract][Full Text] [Related]
16. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
Kirkali Z
BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
[TBL] [Abstract][Full Text] [Related]
17. Adverse events of targeted therapies.
Klastersky JA
Curr Opin Oncol; 2014 Jul; 26(4):395-402. PubMed ID: 24825019
[TBL] [Abstract][Full Text] [Related]
18. Non-rash dermatologic adverse events related to targeted therapies.
Bryce J; Boers-Doets CB
Semin Oncol Nurs; 2014 Aug; 30(3):155-68. PubMed ID: 25085027
[TBL] [Abstract][Full Text] [Related]
19. [Molecular targeted therapy for advanced renal cell carcinoma].
Kanayama H
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
Reyes-Habito CM; Roh EK
J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]